XBiotech USA, Inc. - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 40 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

XBiotech USA, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'XBiotech USA, Inc. - Product Pipeline Review - 2014', provides an overview of the XBiotech USA, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of XBiotech USA, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of XBiotech USA, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of XBiotech USA, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the XBiotech USA, Inc.'s pipeline products

Reasons to buy

- Evaluate XBiotech USA, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of XBiotech USA, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the XBiotech USA, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of XBiotech USA, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of XBiotech USA, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of XBiotech USA, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
XBiotech USA, Inc. Snapshot 5
XBiotech USA, Inc. Overview 5
Key Information 5
Key Facts 5
XBiotech USA, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
XBiotech USA, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
XBiotech USA, Inc. - Pipeline Products Glance 11
XBiotech USA, Inc. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
XBiotech USA, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
XBiotech USA, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
XBiotech USA, Inc. - Drug Profiles 16
Xilonix 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CV-18C3 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
RA-18C3 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
T2-18C3 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CA-18C3 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
MABp-1 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Biosimilar for Inflammation 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Biosimilar for Oncology 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
filgrastim 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MonoClonal Antibody for Methicillin Resistant Staphylococcus Aureus 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibody to Inhibit IL-1A for Rheumatoid Arthritis and Myeloma 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclonal Antibody for Influenza 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibody for Vascular diseases 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibody to Inhibit Interleukin-6 for Autoimmune Disorder and Transplantation 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
XBiotech USA, Inc. - Pipeline Analysis 32
XBiotech USA, Inc. - Pipeline Products by Target 32
XBiotech USA, Inc. - Pipeline Products by Route of Administration 33
XBiotech USA, Inc. - Pipeline Products by Molecule Type 34
XBiotech USA, Inc. - Pipeline Products by Mechanism of Action 35
XBiotech USA, Inc. - Recent Pipeline Updates 36
XBiotech USA, Inc. - Locations And Subsidiaries 38
Head Office 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
XBiotech USA, Inc., Key Information 5
XBiotech USA, Inc., Key Facts 5
XBiotech USA, Inc. - Pipeline by Indication, 2014 8
XBiotech USA, Inc. - Pipeline by Stage of Development, 2014 9
XBiotech USA, Inc. - Monotherapy Products in Pipeline, 2014 10
XBiotech USA, Inc. - Phase III, 2014 11
XBiotech USA, Inc. - Phase II, 2014 12
XBiotech USA, Inc. - Phase I, 2014 13
XBiotech USA, Inc. - Preclinical, 2014 14
XBiotech USA, Inc. - Discovery, 2014 15
XBiotech USA, Inc. - Pipeline by Target, 2014 32
XBiotech USA, Inc. - Pipeline by Route of Administration, 2014 33
XBiotech USA, Inc. - Pipeline by Molecule Type, 2014 34
XBiotech USA, Inc. - Pipeline Products by Mechanism of Action, 2014 35
XBiotech USA, Inc. - Recent Pipeline Updates, 2014 36